Effect of medroxyprogesterone injection on liver function and histological features of the liver in albino rats

Alassaf,Fawaz A.; Abed,Mohammed N.; Qazzaz,Mohannad E.

doi:10.3892/wasj.2025.341

Effect of medroxyprogesterone injection on liver function and histological features of the liver in albino rats

Authors:
- Fawaz A. Alassaf
- Mohammed N. Abed
- Mohannad E. Qazzaz
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul, Mosul, Nineveh Governorate 41002, Iraq, Department of Clinical Laboratory Sciences, College of Pharmacy, University of Mosul, Mosul, Nineveh Governorate 41002, Iraq, Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, University of Mosul, Mosul, Nineveh Governorate 41002, Iraq
Published online on: April 2, 2025 https://doi.org/10.3892/wasj.2025.341
Article Number: 53
Copyright : © Alassaf et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Medroxyprogesterone is a synthetic progestin that is widely used as a hormonal contraceptive and has a potential for hepatotoxicity. The present study aimed to evaluate the effects of medroxyprogesterone administration on the hepatic functions of female albino rats. For this purpose, a total of 20 female albino rats were divided into two groups of 10 rats each. The first group represented the rats prior to medroxyprogesterone administration, and the second group included the same rats after receiving an intramuscular injection of medroxyprogesterone (3.5 mg/rat/week) following an 8‑week study period. In addition, the study included group 3, which represented the control female albino rats at the start of the study and group 4 represented the same rats of group 3, but at the end of the experiment. Blood samples were obtained for the evaluation of liver function, including the analysis of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin levels. Additionally, samples of hepatic tissues were histologically assessed. The results revealed a statistically significant elevation in AST, ALT and total bilirubin levels, with a reduction in ALP levels in the treated group (group 2) compared to the other groups at P<0.001. The histopathological examination of the liver tissues revealed the vacuolar degeneration of hepatocytes, the congestion of sinusoids and inflammation in the treated group compared to the control groups. These findings point to the negative impact of medroxyprogesterone on rat liver function, with hepatic cell injury being observed. These findings highlight the potential hepatotoxic effects of this drug and urges the routine monitoring of liver function in clinical settings.

View Figures

View References

1	Darroch JE: Trends in contraceptive use. Contraception. 87:259–263. 2013.PubMed/NCBI View Article : Google Scholar
2	Tandulwadkar S, Gupta S, Singh A, Mishra S and Singhania S: Medroxyprogesterone acetate versus gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles. JBRA Assist Reprod. 27(15)2023.PubMed/NCBI View Article : Google Scholar
3	Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C and Walling M: Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann. 25:69–76. 1999.PubMed/NCBI
4	Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, et al: Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian cancer: The mounting evidence of a protective role of progestins. Cancer Epidemiol Biomarkers Prev. 30:927–935. 2021.PubMed/NCBI View Article : Google Scholar
5	Heffron R, Achilles SL, Dorflinger LJ, Hapgood JP, Kiarie J, Polis CB and Steyn PS: Pharmacokinetic, biologic and epidemiologic differences in MPA-and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women. Contraception. 99:199–204. 2019.PubMed/NCBI View Article : Google Scholar
6	Abed MN, Qazzaz ME and Alassaf FA: Investigating the nephrotoxic effects of medroxyprogesterone in female albino rats. Ukr J Nephrol Dial. 2024:25–33. 2024.
7	Sathe A and Gerriets V: Medroxyprogesterone. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559192/.
8	Baik SH, Baye F and McDonald CJ: Effects of hormone therapy on survival, cancer, cardiovascular and dementia risks in 7 million menopausal women over age 65: A retrospective observational study. medRxiv: May 26, 2022 (Epub ahead of print).
9	Ramazonovna KS: Differential diagnosis and treatment of depressive disorders in women during menopause. Eur J Innov Nonform Educ. 2:23–30. 2022.
10	Hosseinzadeh P and Wild R: Role of lipid management in women's health preventive care. Obstet Gynecol Clin. 48:173–191. 2021.PubMed/NCBI View Article : Google Scholar
11	Özcan Ö, Den Elzen WPJ, Hillebrand JJ, Den Heijer M, Van Loendersloot LL, Fischer J, Hamer H, de Jonge R and Heijboer AC: The effect of hormonal contraceptive therapy on clinical laboratory parameters: A literature review. Clin Chem Lab Med. 62:18–40. 2024.PubMed/NCBI View Article : Google Scholar
12	Trinh A, Vyas A, Roselle A, Velu D, Hota L and Kadiyala M: Contraception and Cardiovascular Effects: What Should the Cardiologist Know? Curr Cardiol Rep. 25:1489–1498. 2023.PubMed/NCBI View Article : Google Scholar
13	Björnsson ES: Drug-induced cholestasis. In: Cholestatic Liver Disease. Carey EJ and Lindor KD (eds). Springer, New York, NY, pp13-31, 2014. Available from: https://doi.org/10.1007/978-1-4939-1013-7_2.
14	Kapp N: WHO provider brief on hormonal contraception and liver disease. Contraception. 80:325–326. 2009.PubMed/NCBI View Article : Google Scholar
15	Sitruk-Ware R: Reprint of pharmacological profile of progestins. Maturitas. 61:151–157. 2008.PubMed/NCBI View Article : Google Scholar
16	Mukherjea M, Mukherjee P, Biswas R, Chakraborty AS and Kushari J: Effect of medroxyprogesterone acetate contraception on human serum enzymes. Int J Fertil. 26:35–39. 1981.PubMed/NCBI
17	Connolly TJ and Zuckerman AL: Contraception in the patient with liver disease. Semin Perinatol. 22:178–182. 1998.PubMed/NCBI View Article : Google Scholar
18	Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ and Whiteman MK: US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 65:1–103. 2016.PubMed/NCBI View Article : Google Scholar
19	Itriyeva K: Use of Long-acting reversible contraception (LARC) and the Depo-provera shot in adolescents. Curr Probl Pediatr Adolesc Health Care. 48:321–332. 2018.PubMed/NCBI View Article : Google Scholar
20	Sathe A and Gerriets V: Medroxyprogesterone. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559192/.
21	Abd-Elkareem M, Alnasser SM, Meshal A, Abdullah RI and Ali AU: The effect of Norethisterone acetate on the uterus of albino rats: Histological, histochemical and ultrastructure study. BMC Vet Res. 20(384)2024.PubMed/NCBI View Article : Google Scholar
22	Chisholm NC and Juraska JM: Effects of long-term treatment with estrogen and medroxyprogesterone acetate on synapse number in the medial prefrontal cortex of aged female rats. Menopause. 19:804–811. 2012.PubMed/NCBI View Article : Google Scholar
23	Chane E, Wondifraw H, Hadgu R and Fasil A: Assessment of liver function tests of women taking hormonal contraceptives at University of Gondar comprehensive specialized hospital and Family Guidance Association of Gondar (FGAE), 2022; a comparative cross-sectional study. PLoS One. 18(e0289746)2023.PubMed/NCBI View Article : Google Scholar
24	Ebele JI, Emeka EN, Ignatius CM, Peace UN and Ebele E: Effects of duration of use of hormonal contraceptives on liver function. Res J Med Sci. 3:52–55. 2009.
25	Faddah L, Al-Rehany M, Abdel-Hamid N and Bakeet A: Oxidative stress, lipid profile and liver functions in average Egyptian long term depo medroxy progesterone acetate (DMPA) users. Molecules. 10:1145–1152. 2005.PubMed/NCBI View Article : Google Scholar
26	Iluz-Freundlich D, Zhang M, Uhanova J and Minuk GY: The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. Ann Hepatol. 19:204–208. 2020.PubMed/NCBI View Article : Google Scholar
27	Ribeiro AJS, Yang X, Patel V, Madabushi R and Strauss DG: Liver microphysiological systems for predicting and evaluating drug effects. Clin Pharmacol Ther. 106:139–147. 2019.PubMed/NCBI View Article : Google Scholar
28	Kowalska K, Ściskalska M, Bizoń A, Śliwińska-Mossoń M and Milnerowicz H: Influence of oral contraceptives on lipid profile and paraoxonase and commonly hepatic enzymes activities. J Clin Lab Anal. 32(e22194)2018.PubMed/NCBI View Article : Google Scholar
29	Rahim SA: Activities of some liver enzymes in serum of woman receiving oral contraceptives, injection and Cu-IUD. Eur Asian J Biosci: 14, 2020.
30	Taheri M, Rahimi M, Naderi M, Ghavami S, Mokhtari M, Rashidi H and Hashemi M: Effects of a subdermal levonorgestrel contraceptive implant (Norplant) on serum cholesterol, triglycerides, ALT and AST in Iranian women. Contraception. 73:56–58. 2006.PubMed/NCBI View Article : Google Scholar
31	Oh RC, Hustead TR, Ali SM and Pantsari MW: Mildly elevated liver transaminase levels: Causes and evaluation. Am Fam Physician. 96:709–715. 2017.PubMed/NCBI
32	Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, et al: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 137:1–10. 2002.PubMed/NCBI View Article : Google Scholar
33	Shosha HM, Ebaid HM, Toraih EA, Abdelrazek HMA and Elrayess RA: Effect of monosodium glutamate on fetal development and progesterone level in pregnant Wistar Albino rats. Environ Sci Pollut Res. 30:49779–49797. 2023.PubMed/NCBI View Article : Google Scholar
34	Coombes Z, Plant K, Freire C, Basit AW, Butler P, Conlan RS and Gonzalez D: Progesterone metabolism by human and rat hepatic and intestinal tissue. Pharmaceutics. 13(1707)2021.PubMed/NCBI View Article : Google Scholar
35	Serfaty D: Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 48:297–307. 2019.PubMed/NCBI View Article : Google Scholar
36	Egoro ET, Tokoni OG and Anakwe CS: Studies on some plasma biochemical parameters in short and long term users of oral contraceptives containing lower doses of estrogen and progestin composition in Lagos, Nigeria. Health (NY). 1(2)2018.
37	Onyesom I, Osioma E, Etagar E and Ofili M: Activities of some liver enzymes in serum of humans receiving DMPA and CUPID contraceptives. Sch J App Med Sci. 1:62–64. 2013.
38	Bakry S and Abu-Shaeir W: Electrophoretic and histopathologica l studies on adult female rats treated with depo-provera (DMPA). Aust J Basic Appl Sci. 4:61–70. 2010.
39	Ahmed O, Robinson MW and O'Farrelly C: Inflammatory processes in the liver: Divergent roles in homeostasis and pathology. Cell Mol Immunol. 18:1375–1386. 2021.PubMed/NCBI View Article : Google Scholar
40	Masama C, Jarkas DA, Thaw E, Daneshmend AZ, Franklyn SI, Beaurepaire C and McQuaid RJ: Hormone contraceptive use in young women: Altered mood states, neuroendocrine and inflammatory biomarkers. Horm Behav. 144(105229)2022.PubMed/NCBI View Article : Google Scholar
41	Chen P, Yao L, Yuan M, Wang Z, Zhang Q, Jiang Y and Li L: Mitochondrial dysfunction: A promising therapeutic target for liver diseases. Genes Dis. 11(101115)2024.PubMed/NCBI View Article : Google Scholar